MIMETAS is a brand that offers innovative solutions for drug discovery and development. They specialize in the OrganoPlate® platform, which enables the creation of novel human tissue and disease models. Their services include custom model and assay development, compound profiling and screening, and other drug discovery support services.

With robust compound data obtained from human tissue models, they assist in accelerating the drug discovery and development process. MIMETAS offers a wide range of products, including various configurations of the OrganoPlate® that support different numbers of tissue models. They also provide the OrganoPlate® Graft, the first in vitro tissue culture platform that allows co-culture of spheroids, organoids, and tumors with a perfused microvascular bed.

To facilitate the adoption of 3D tissue modeling, MIMETAS offers OrganoStart packages, which allow researchers to kickstart their first experiments with the OrganoPlate®. Additionally, they provide OrganoReady® products, which are ready-to-use tissue models pre-seeded with specific cells for drug exposure, transport, and permeability studies. MIMETAS also offers instruments like OrganoFlow® for precisely-controlled perfusion flow and OrganoTEER® for fast and automated TEER measurements in the OrganoPlate® platform.

Overall, MIMETAS provides comprehensive solutions and support for researchers in the field of drug discovery, enabling them to study relevant 3D tissue biology and accelerate the development of therapeutics